Day 1 :
Nizam’s Institute of Medical Sciences, India
Keynote: Imaging of Mediastinal Masses
Time : 9:00-9:25
Kakarla Subbarao is former director and vice chancellor of Nizam’s Institution of Medical Sciences, Hyderabad, India. He is also former advisor to Govt. of AP in Health medicine and family welfare, former professor of radiology, Osmania Medical College, Hyderabad, India & Albert Einstein College of Medicine, New York, USA. Presently, he is Emeritus professor of radiology, Nizam’s Institution of Medical Sciences, Hyderabad, Chairman, KIMS Foundation and Research Centre, Secunderabad, India and President of Musculoskeletal Society, India.
Mediastinum means standing in middle. Mediastinal masses include cystic and solid tumors. They may be benign or malignant. Occasionally, inflammatory lesions may also pose as tumors. rnrnRadiologically mediastinum is identified and classified into three major portions particularly in the lateral view of plain radiographs. Several authors have given their own classification of mediastinum. However, Felson’s classification has been more popular and more practical. This classification is quite helpful in locating and identifying mediastinal masses to the extent of making a histological diagnosis. Although, conventional radiographs which include PA and lateral views serve to locate the masses in the major three compartments, advanced imaging such as MDCT and MRI provide a final diagnosis. However, the ultimate diagnosis is derived from a biopsy. Depending upon the compartment of the mediastinum different masses can be identified.
Ace-Probe Technologies Pvt. Ltd, India
Time : 9:25-9:50
Puneet Chandna is a PhD in Biophysics from University of Edinburgh, U K with over 23 years of experience in the field of instrumentation, technology and life sciences. Currently he is Working Partner and Collaborator at Tata Memorial Centre and Hospital, Mumbai. His dissertation and thesis work has been on exploration and synthesis of Hybrid particles. Multi disciplines of his extended study and practice to include certifications for expert evaluation, prognosis & management of symptom and side effects in the field of oncology, diabetes etc., from several institutes to include leading international centers such as Harvard, OHIO State University, University of Pennsylvania etc.
Personalized medicine, serviced through advances in genomics, continues to evolve as rapidly advancing expanse in modern day medicine. Growing list of scientific discoveries has significantly changed the traditional practice of medicine, compelling us to adopt this, novel approach in daily patient care setting. It continues to affect and create advanced multidisciplinary approach for patient care with Targeted therapy, risk assessment, diagnosis and screening protocols now being planted with a molecular engagement in their concerned pathways.rnrnOncologists, pathologists and basic scientists are all aggressively etching the countenance of futuristic medicine with combative projects and clinical trials , planned contentiously to include research in cancer molecular diagnostics and therapy related questions with genomics as a potential modifier, and not as a mere contributor. Quest to discover and validate biomarkers such as Mutations, Polymorphisms and epigenomics are being considered for, therapy selection, prognosis, diagnosis and have become a hallmark of perspectives of quality, guidelines and regulations, particularly in cancer, a molecular disease.rnrnInformed choice, evidence and an integrated approach, all add up to a rich resource for non-specialized to a growing argument in the way we treat with specialized comprehension in mind. Environmental factors and nutrition are gaining importance with their ability to transform a strong and established link to human genetic profile that gives rise to a genetic predisposition or life cycle of a disease, appropriating a large area of present-day, state of the art, affirmative approach to treat better.